Rybelsus is the current UK oral semaglutide anchor. U.S. oral Wegovy, U.S. Ozempic tablets and Foundayo are label-level developments with U.S.-specific evidence. The table separates product, molecule, route, indication, dose form, administration rule, safety warnings and UK meaning.
UK availability needs UK regulator, product-information and access evidence. A U.S. label supplies product facts for the United States; it is not a UK launch, NHS route, private prescribing route or suitability assessment.
Each row is a product-label fact pattern. The last column gives the UK access-status result.
| Product label | Active ingredient | Jurisdiction and status | Label use | Tablet strengths | Administration rule | Escalation / maintenance | UK status result |
|---|---|---|---|---|---|---|---|
| Rybelsus | Semaglutide | UK-relevant current oral anchor | Adults with type 2 diabetes when diet and exercise are not enough, either alone when metformin cannot be used or with other diabetes medicines. | UK eMC PIL lists 1.5 mg, 4 mg and 9 mg tablets. | Take after at least 8 hours fasting; swallow whole with water up to 120 mL; wait at least 30 minutes before food, drink or other oral medicines. | Start 1.5 mg once daily for one month; increase to 4 mg; 9 mg may be used if blood sugar is not controlled well enough. | Rybelsus establishes a real oral GLP-1 tablet route in UK practice. GOV.UK places Rybelsus in the diabetes context, not as a broad UK weight-loss tablet answer. |
| Wegovy tablets | Semaglutide | U.S. oral semaglutide label fact | U.S. label includes adult weight reduction and cardiovascular-risk reduction indications for tablets. | 1.5 mg, 4 mg, 9 mg and 25 mg tablets. | Take once daily in the morning on an empty stomach with water up to 4 ounces; swallow whole; wait at least 30 minutes before food, drinks or other oral medicines. | Start 1.5 mg once daily for 30 days, then escalate every 30 days; recommended maintenance tablet dose is 25 mg once daily for listed adult tablet indications. | Important U.S. oral-weight-management context. Current UK oral Wegovy access would need UK regulator and prescribing-route evidence. |
| Ozempic tablets | Semaglutide | U.S. oral semaglutide label fact | U.S. label groups Rybelsus and Ozempic tablets for adults with type 2 diabetes, including glycaemic control and major adverse cardiovascular event risk reduction in high-risk adults. | Ozempic tablets: 1.5 mg, 4 mg and 9 mg. | Same oral semaglutide administration pattern in the U.S. label: empty stomach in the morning, water up to 4 ounces, swallow whole, wait at least 30 minutes. | Start 1.5 mg once daily for 30 days; increase to 4 mg; 9 mg may be used if additional glycaemic control is needed. | Explains why “Ozempic pill” is visible in U.S. materials. The current UK oral semaglutide tablet answer remains Rybelsus. |
| Foundayo | Orforglipron | U.S. FDA approval dated 1 April 2026 | U.S. chronic weight-management indication in adults with obesity or overweight plus at least one weight-related comorbid condition, with diet and physical activity. | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg tablets. | Take orally once daily, with or without food; swallow whole; do not break, crush or chew; do not take more than one tablet per day. | Start 0.8 mg once daily; increase after at least 30 days to 2.5 mg, then 5.5 mg; later levels can be 9 mg, 14.5 mg or 17.2 mg once daily based on response and tolerability. | Foundayo broadens the U.S. oral category beyond semaglutide. It is orforglipron, and no current UK access route is identified here. |
The administration routine changes fasting, water, timing, dose escalation and interaction checks. Label comparison needs product-specific wording.
| Routine point | Rybelsus / oral semaglutide pattern | Wegovy tablets U.S. | Foundayo U.S. | Practical status result |
|---|---|---|---|---|
| Fasting | UK Rybelsus PIL says after a recommended fasting period of at least 8 hours. | U.S. Wegovy tablet label says empty stomach in the morning. | No fasting requirement in the U.S. label; with or without food. | Not every GLP-1 tablet has the same routine. “Tablet” is not one practical experience. |
| Water | Up to 120 mL in the UK Rybelsus PIL. | Up to 4 ounces in the U.S. Wegovy tablet label. | No matching water-volume restriction in the headline administration instructions. | Water limits are central to oral semaglutide administration and are not assumed for orforglipron. |
| Waiting period | At least 30 minutes before eating, drinking or taking other oral medicines. | At least 30 minutes before food, beverages or other oral medicines. | No 30-minute empty-stomach wait in the U.S. label administration bullets. | Foundayo’s U.S. routine is a label fact; convenience does not equal UK availability. |
| Tablet integrity | Swallow whole; do not split, crush or chew. | Swallow whole; do not split, crush, chew or dissolve. | Swallow whole; do not break, crush or chew. | All rows keep the tablet whole. Cutting or crushing is not a safe shortcut. |
| Missed dose | UK Rybelsus PIL says skip the missed dose and take the normal dose the next day. | Follow the U.S. Wegovy tablet label for tablet-specific missed-dose and switching instructions. | U.S. label says take the missed dose as soon as possible, do not double up the next dose, and reinitiate lower-dose escalation after 7 or more missed consecutive doses. | Missed-dose rules differ by product. A general “GLP-1 tablet” answer is not enough. |
Tablet form does not remove prescription-only status, clinical screening, side-effect monitoring or urgent-warning rules.
Rybelsus UK patient information and U.S. GLP-1 labels include pancreatitis warnings. UK public guidance also highlights severe stomach pain radiating to the back as an urgent sign.
Vomiting, diarrhoea and poor fluid intake matter because GLP-1 labels and GOV.UK guidance connect severe gastrointestinal effects with dehydration risk.
UK guidance and Rybelsus patient information include NAION or sudden vision-change warnings for semaglutide.
GOV.UK guidance lists at least 2 months before pregnancy for semaglutide products. Label facts need reproductive-safety guidance beside them.
These checks turn label facts into a practical UK status answer. A U.S. prescribing label, a UK patient leaflet, a regulator approval and an NHS route each prove different things.
| UK question | Evidence that would answer it | What current label data supports | What current label data cannot support | Current site answer |
|---|---|---|---|---|
| Is the tablet licensed in the UK? | MHRA-authorised UK product information, eMC SmPC/PIL, or official UK regulator communication naming the product, route and indication. | Rybelsus has UK patient information for oral semaglutide tablets. U.S. labels support U.S. tablet facts for Wegovy tablets, Ozempic tablets and Foundayo. | A U.S. label cannot prove UK licensing, UK launch, UK prescribing or UK pharmacy supply. | Rybelsus is the current UK oral GLP-1 anchor. U.S. oral Wegovy/Ozempic tablet labels and Foundayo remain country-labelled U.S. facts unless UK sources change. |
| Is it a UK weight-management tablet? | UK product information and UK public guidance showing the oral route is authorised for weight management, plus route-specific access information. | U.S. Wegovy tablets and Foundayo labels support U.S. weight-management tablet context. Rybelsus supports a UK oral semaglutide tablet in the diabetes context. | Rybelsus being a tablet does not make it a UK weight-loss tablet; U.S. weight-management labels do not create UK weight-management access. | No broad current UK oral GLP-1 weight-loss tablet market is established from the sources checked on 1 May 2026. |
| Can it be obtained through the NHS? | NICE guidance, NHS service criteria, local formulary information, and prescribing pathway details for the specific product, route and indication. | Labels identify products and labelled uses; GOV.UK confirms GLP-1 medicines are prescription-only and access varies by location and treatment purpose. | Licensing and label records answer product-status questions. NHS access also needs pathway, eligibility, local service and supply evidence. | NHS access is pathway-specific, not implied by a label or headline. |
| Can it be prescribed privately in the UK? | UK legal prescribing route, regulated prescriber assessment, legitimate pharmacy supply and product-specific UK status. | GOV.UK supports the rule that private GLP-1 access still requires a healthcare consultation and prescription-only supply. | Online visibility, social media adverts, beauty-salon offers or overseas product names do not prove a legitimate UK private route. | A private route is meaningful only when the product is legally supplied through regulated clinical checks and a legitimate pharmacy. |
| Is the medicine suitable for an individual? | Clinical assessment covering indication, contraindications, pregnancy plans, other medicines, diabetes status, eye symptoms, gastrointestinal history and side-effect risk. | Labels and GOV.UK guidance identify safety areas that clinicians need to consider, including pancreatitis, dehydration/kidney risk, NAION, pregnancy and medicine interactions. | A product table cannot decide suitability, dose choice, switching, stopping or monitoring for an individual person. | This table is informational only; product suitability needs a qualified prescriber or healthcare professional. |
| Are the brand names interchangeable? | Product identity evidence naming brand, active ingredient, route, indication and country status. | Rybelsus, Wegovy tablets and Ozempic tablets are semaglutide labels in different product/route/country contexts. Foundayo is orforglipron. | Shared GLP-1 category wording does not make semaglutide and orforglipron the same molecule, or make Rybelsus, Wegovy, Ozempic and Foundayo the same access answer. | Compare by molecule first, then brand, route, country, indication and access route. |
Source basis: UK tablet strengths, fasting, water, waiting, missed-dose and safety wording.
Source basis: product identity and diabetes context.
Source basis: U.S. oral Wegovy tablet strengths, administration, indications and warnings.
Source basis: U.S. oral semaglutide tablet dosing and Ozempic-tablet context.
Source basis: orforglipron strengths, indication, administration, escalation, interactions and warnings.
Source basis: UK prescription-only access, unsafe supply, pregnancy/contraception and safety framing.